We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic
Read MoreHide Full Article
Zimmer Biomet Holdings, Inc.'s (ZBH - Free Report) slow recovery in the Americas amid the emergence of a new strain of coronavirus remains a major concern. The company currently has a Zacks Rank #4 (Sell).
In the past six months, Zimmer Biomet has underperformed its industry. The stock has declined 28.5% compared with a 9.7% fall of the industry.
Zimmer Biomet ended the third quarter of 2021 with a lower-than-expected revenue figure. The year-over-year decline in reported and constant currency revenues was concerning. Sales were soft in the Americas. In terms of operating segments, the company’s core divisions like Knees, Hips, and Dental & Spine registered significant year-over-year declines in revenues at CER.
In the quarter, Zimmer Biomet continued to face COVID-induced challenges and market pressure. According to the company, the third quarter was full of unexpected negative environmental impacts that were mostly out of control. The quarter brought greater COVID pressure than expected for Zimmer Biomet. According to Zimmer Biomet, the business recovery continued in August but then declined in September with the rise in Delta variant cases and increase in staffing shortage.
Significant margin contractions and a slashed 2021 guidance are concerns too.
After excluding intangible asset amortization, the gross margin was 69.8%, reflecting a contraction of 71 basis points (bps) in the third quarter. Selling, general and administrative expenses were up 1.6%. Research and development expenses rose 26.8%. Adjusted operating margin contracted 268 bps to 22.4% during the quarter.
This time, on a dismal quarterly performance, the company slashed its financial guidance for 2021. Reported revenue growth is expected in the range of 11.3% to 12.5% (from the earlier expectation of 14.5% to 16.5%) compared with the last year. Adjusted EPS for the full year is expected in the range of $7.32 to $7.47 ($7.65 to $7.95).
On a positive note, Zimmer Biomet ended the third quarter with better-than-expected earnings. In the quarter, the company saw an improving trend across a number of markets. Geographically, in the third quarter, EMEA grew 5.9% year over year, up 0.3% from the 2019 pre-pandemic level. According to Zimmer Biomet, this was the first time that the region posted growth since the start of the pandemic. Asia Pacific grew 0.5% year over year, up from the 2019 pre-pandemic level.
In terms of operating segments, the sports extremity and trauma category increased 4.2% or 7.7% from the 2019 level, driven by continuing commercial specialization, new product introductions and the contribution from strategic acquisitions. The company’s ‘Other’ category grew 15.4% year over year driven by the ongoing demand for ROSA Knee as well as increased revenues from the launch of ROSA partial knee and hip applications.
Moreover, Zimmer Biomet’s spin-off decision of the non-core dental and spine business is expected to prove strategic.
Apollo Endosurgery has a long-term earnings growth rate of 7%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 25.6%, on average.
Apollo Endosurgery has outperformed its industry over the past year. APEN has gained 131.2% compared with the industry’s growth of 7.7%.
Varex has a long-term earnings growth rate of 5%. The company surpassed earnings estimates in the trailing four quarters, delivering an average surprise of 115.3%.
Varex has outperformed the industry it belongs to in the past year. VREX has gained 79.4% compared with the industry’s 6.2% fall.
Thermo Fisher has a long-term earnings growth rate of 14%. The company surpassed earnings estimates in the trailing four quarters, delivering an average surprise of 9%.
Thermo Fisher has outperformed its industry over the past year. TMO has rallied 40.7% compared with the industry’s 7.7% rise.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic
Zimmer Biomet Holdings, Inc.'s (ZBH - Free Report) slow recovery in the Americas amid the emergence of a new strain of coronavirus remains a major concern. The company currently has a Zacks Rank #4 (Sell).
In the past six months, Zimmer Biomet has underperformed its industry. The stock has declined 28.5% compared with a 9.7% fall of the industry.
Zimmer Biomet ended the third quarter of 2021 with a lower-than-expected revenue figure. The year-over-year decline in reported and constant currency revenues was concerning. Sales were soft in the Americas. In terms of operating segments, the company’s core divisions like Knees, Hips, and Dental & Spine registered significant year-over-year declines in revenues at CER.
In the quarter, Zimmer Biomet continued to face COVID-induced challenges and market pressure. According to the company, the third quarter was full of unexpected negative environmental impacts that were mostly out of control. The quarter brought greater COVID pressure than expected for Zimmer Biomet. According to Zimmer Biomet, the business recovery continued in August but then declined in September with the rise in Delta variant cases and increase in staffing shortage.
Significant margin contractions and a slashed 2021 guidance are concerns too.
Zimmer Biomet Holdings, Inc. Price
Zimmer Biomet Holdings, Inc. price | Zimmer Biomet Holdings, Inc. Quote
After excluding intangible asset amortization, the gross margin was 69.8%, reflecting a contraction of 71 basis points (bps) in the third quarter. Selling, general and administrative expenses were up 1.6%. Research and development expenses rose 26.8%. Adjusted operating margin contracted 268 bps to 22.4% during the quarter.
This time, on a dismal quarterly performance, the company slashed its financial guidance for 2021. Reported revenue growth is expected in the range of 11.3% to 12.5% (from the earlier expectation of 14.5% to 16.5%) compared with the last year. Adjusted EPS for the full year is expected in the range of $7.32 to $7.47 ($7.65 to $7.95).
On a positive note, Zimmer Biomet ended the third quarter with better-than-expected earnings. In the quarter, the company saw an improving trend across a number of markets. Geographically, in the third quarter, EMEA grew 5.9% year over year, up 0.3% from the 2019 pre-pandemic level. According to Zimmer Biomet, this was the first time that the region posted growth since the start of the pandemic. Asia Pacific grew 0.5% year over year, up from the 2019 pre-pandemic level.
In terms of operating segments, the sports extremity and trauma category increased 4.2% or 7.7% from the 2019 level, driven by continuing commercial specialization, new product introductions and the contribution from strategic acquisitions. The company’s ‘Other’ category grew 15.4% year over year driven by the ongoing demand for ROSA Knee as well as increased revenues from the launch of ROSA partial knee and hip applications.
Moreover, Zimmer Biomet’s spin-off decision of the non-core dental and spine business is expected to prove strategic.
Key Picks
A few better-ranked stocks in the broader medical space are Apollo Endosurgery, Inc. , Varex Imaging Corporation (VREX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Apollo Endosurgery has a long-term earnings growth rate of 7%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 25.6%, on average.
Apollo Endosurgery has outperformed its industry over the past year. APEN has gained 131.2% compared with the industry’s growth of 7.7%.
Varex has a long-term earnings growth rate of 5%. The company surpassed earnings estimates in the trailing four quarters, delivering an average surprise of 115.3%.
Varex has outperformed the industry it belongs to in the past year. VREX has gained 79.4% compared with the industry’s 6.2% fall.
Thermo Fisher has a long-term earnings growth rate of 14%. The company surpassed earnings estimates in the trailing four quarters, delivering an average surprise of 9%.
Thermo Fisher has outperformed its industry over the past year. TMO has rallied 40.7% compared with the industry’s 7.7% rise.